Sglt2 Inhibitors And Glp1 Receptor Agonists Reduce All-Cause Mortality Among Other Patient Benefits

SGLT2 Inhibitors and GLP1 Receptor Agonists Reduce All-Cause Mortality Among Other Patient Benefits

Family & Community Medicine Grand Rounds

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In

Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Harvard Medical School Continuing Education

Jeffrey Berger, MD: Deciding Between GLP1 Agonists or SGLT2 Inhibitors

Type 2 Diabetes: The Effects of Different Antidiabetic Drug Classes on Mortality

Fundamentals of SGLT2i's and GLP-1RA's for CV Risk

American College of Cardiology

DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies in the Time of COVID-19

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'

At the Limits - Leading Medical Education

EASD 2023 - Benefits of SGLT2 inhibitors and GLP-1 receptor agonists beyond glycaemic control

European Association for the Study of Diabetes

Exploring the Science and Practice of GLP-1 Receptor Agonists

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital Setting

University of Ottawa Heart Institute

Is One SGLT2 (Or GLP-1) Just Like Another for Cardiac Benefit?

Diabetes and Cardiovascular Disease, SGLT2 inhibitors and GLP1 receptor agonists with Dr. Peter Toth

Future Pulse Cardiology

SGLT-2 Inhibitors for Type 2 Diabetes - Amel Arnaout, MD

University of Ottawa Heart Institute

CKD E-Learning - SGLT-2 inhibitors and CKD - 05.19.21

Cardiovascular Risk Reduction with SGLT2 inhibitors and GLPl Agonists

Emory Cardiology

Evolution of SGLT2 Inhibitors from management of glycemic control , Dr. Sanjay Kaul, MD

MonteHeart Lectures

Individualizing Treatment With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

Exploring Advances in GLP-1 Agonist Therapy